Blood-based testing for advanced adenoma
Active Cooperative Agreement Awarded Last action
- Award ID
- U01CA271884
- Recipient
-
University Of Pittsburgh - Of The Commonwealth System Of Higher Education UEI MKAGLD59JRL1
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $6,838,850
Award facts
- Assistance listing
- 93.394 Cancer Detection and Diagnosis Research
- Completion date 76% complete
- Originally
- Funding
-
- $6,109,403.00 Federal
- $729,447.00 Non-federal
- Place of performance
- Pittsburgh, PA 15213, USA
Award details come from USAspending.gov.
Description
- Abstract
- The goal of our clinical validation center (CVC) is to advance and validate blood-based detection of colorectal advanced adenoma. Whereas blood-based testing for invasive colorectal cancer is progressing, with multiple companies pursuing products, the ability of blood-based testing to detect advanced adenomas, the pre- malignant lesions closest to invasive cancer, is uncertain. To optimally impact colorectal cancer incidence, blood-based biomarkers cannot just detect cancer, they should also have sufficient sensitivity to identify subjects with advanced adenomas. For our CVC, we organized and assembled a network of highly skilled clinical centers including a focus on minority populations, to prospectively collect well-characterized, high- quality blood specimens from a large number of subjects with advanced adenoma prior to undergoing polypectomy and serially post-polypectomy. From the same clinical centers, we will collect blood specimens from control subjects. Specimens will be collected and processed using standard protocols, and relevant demographic and clinical variables will be captured to facilitate biomarker validation studies. Specifically, we will use these well-characterized specimens to validate our data on the utility of original, innovative techniques for molecular detection of advanced adenomas including realseqs in combination with custom machine learning algorithms such as signal. We propose two specific aims. In specific aim 1, we will conduct a phase 2 case-control study to validate our novel methods for advanced adenoma detection. We will prospectively recruit patients with advanced adenoma (N=400) and site-specific control subjects (N=400) for comparison to the case subjects. In specific aim 2, we will utilize serial blood specimens systematically collected post- polypectomy from our case subjects to determine whether our novel molecular detection techniques can be used to predict likelihood of recurrence and potentially guide surveillance colonoscopy exams. Advanced adenomas are the important, next frontier in non-invasive colorectal cancer screening, and our CVC is equipped to profoundly advance blood-based detection of advanced adenoma.
Transactions
| Action | Federal | Non-federal | Date |
|---|---|---|---|
| Amendment | $999,847 | $0 | |
| Amendment | $951,275 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $984,970 | $0 | |
| Amendment | $984,970 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $729,447 | $0 | |
| Amendment | $729,447 | $729,447 | |
| Original award | $729,447 | $0 |
Show all 12
Subawards
| Subrecipient | Amount | Awarded |
|---|---|---|
| University Of Kansas Medical Center Research Institute, Inc. | $107,295 | |
| The Johns Hopkins University | $23,618 | |
| The Translational Genomics Research Institute | $550,059 | |
| Trustees Of Indiana University | $43,599 | |
| Baylor College Of Medicine | $35,328 | |
| University Of Kansas Medical Center Research Institute, Inc. | $34,224 | |
| The Johns Hopkins University | $23,618 | |
| Trustees Of Indiana University | $43,599 | |
| The Translational Genomics Research Institute | $202,606 | |
| Trustees Of Indiana University | $36,606 | |
| The Johns Hopkins University | $41,110 | |
| The Translational Genomics Research Institute | $220,353 | |
| Trustees Of Indiana University | $22,067 |
Show all 13
Quick answers
Who received award U01CA271884?
U01CA271884 was awarded to University Of Pittsburgh - Of The Commonwealth System Of Higher Education by National Cancer Institute (National Institutes of Health) on September 12, 2022.
How much is award U01CA271884 worth?
$6,838,850 has been obligated on U01CA271884: $6,109,403 in federal funding and $729,447 in non-federal funding.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award